Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 7, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of shareholding changes rather than a financial performance report.
Material Changes
The primary material change reported is a movement in the GlaxoSmithKline US Retirement Savings Plan ("the Plan") on August 3, 2006. The number of Ordinary Share ADRs held by the fund increased from 17,338,911 to 17,443,903. This transaction occurred at an average price of $55.62.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly details a transaction notified in accordance with Disclosure Rule 3.1.4R(1)(b). The Plan is a discretionary fund where all employees or former employees are potential beneficiaries. Two directors, Dr J P Garnier and Dr M M Slaoui, are noted as potentially interested in the shares held in the fund in the same capacity as other employees.
Key Facts for Investor Verification
- Transaction Date: August 3, 2006 (notified August 4, 2006).
- Entity Involved: GlaxoSmithKline US Retirement Savings Plan.
- Share Change: Increase of 104,992 Ordinary Share ADRs (from 17,338,911 to 17,443,903).
- Average Price: $55.62 per ADR.
- Directors' Interest: Dr J P Garnier and Dr M M Slaoui have potential interests in the fund shares alongside other employees.